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We report the first X-linked creatine-deficiency syndrome caused by a defective creatine transporter. The male index
patient presented with developmental delay and hypotonia. Proton magnetic-resonance spectroscopy of his brain
revealed absence of the creatine signal. However, creatine in urine and plasma was increased, and guanidinoacetate
levels were normal. In three female relatives of the index patient, mild biochemical abnormalities and learning
disabilities were present, to various extents. Fibroblasts from the index patient contained a hemizygous nonsense
mutation in the gene SLC6A8 and were defective in creatine uptake. The three female relatives were heterozygous
for this mutation in SLC6A8, which has been mapped to Xq28.
Creatine and phosphocreatine play essential roles in the
storage and transmission of phosphate-bound energy
(Walker 1979; Wyss and Kaddurah-Daouk 2000). Hu-
mans maintain their creatine pool by biosynthesis and
nutritional uptake. The enzymes involved in the biosyn-
thesis of creatine are arginine:glycine amidinotransfer-
ase and guanidinoacetate methyltransferase (GAMT)
(Walker 1979). Creatine is synthesized primarily in liver
and also in kidney and pancreas. Cellular transport is
of fundamental importance for creatine homeostasis in
tissues void of creatine biosynthesis. Two creatine trans-
porters have been identified that are members of solute-
carrier family 6 (neurotransmitter transporters). The cre-
atine-transporter gene, now called “SLC6A8” (MIM
300036), also known as “CT1” or “CRTR,” has been
mapped to Xq28 (Gregor et al. 1995). This gene is ex-
pressed in most tissues, with highest levels in skeletal
muscle and kidney and somewhat lower levels in colon,
brain, heart, testis, and prostate (Nash et al. 1994; Sora
et al. 1994). The creatine-transporter gene SLC6A10,
also known as “CT2,” has been mapped to 16p11 and
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is expressed in testis only (Iyer et al. 1996; Xu et al.
1997). Recently, an inborn error of creatine biosynthesis
was identified as a result of GAMT deficiency (Sto¨ckler
et al. 1996a, 1996b; Schulze et al. 1997; van der Knaap
et al. 2000).
Our index patient, a white male child, was diagnosed
with mild mental retardation at age 6 years and showed
severe delay both in speech and in expressive-language
function. Proton magnetic-resonance spectroscopy
(MRS) of the brain revealed an almost complete absence
of the creatine signal (Cecil et al. 2001), as is observed
in patients with GAMT deficiency (Sto¨ckler et al. 1996a,
1996b; Schulze et al. 1997; van der Knaap et al. 2000).
However, guanidinoacetate (GUAC) in urine and plasma
was normal (table 1). Thus, GAMT deficiency was ruled
out. Creatine levels were increased in urine and plasma.
Supplementation of creatine monohydrate, at 340 mg/
kg body wt/d for 3 mo, did not result in either improved
clinical condition or increased creatine signal in MRS of
the brain (Cecil et al. 2001). The index patient is the
only child of healthy parents, although both his mother
and his maternal grandmother have a history of learning
disability. The mother has two siblings, a healthy sister
and a severely retarded brother; the mother’s brother
was not available for further study. Metabolic workup
of the three female relatives of the index patient (his
mother, his grandmother, and his aunt) showed normal
GUAC in plasma and urine (table 1). In plasma, creatine
levels were found to be normal for the maternal grand-
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Table 1
Metabolic Workup of Family with Creatine Deficiency
SUBJECT(S)
CREATINEa GUACa
Plasma
(mM)
Urine
(mM)
Plasma
(mM)
Urine
(mmol/mol
creatinine)
Index patient 75 2.2 1.1 74
Mother 176b 16b 1.4b 40b
Aunt 143 1.6 2.1 45
Grandmother 32 1.1 2.1 30
Controls
Males 15–44c !.35c
Females 30–80c !.70c
Children .7–1.4d 10–99d
Adults .7–3.5e
a Quantified by stable isotope–dilution GCMS, as described else-
where (Struys et al. 1998); except for creatine measurements, 2H3-
creatine (CDN Isotopes) was used as the internal standard.
b During creatine treatment.
c From Kaplan and Pesce (1989).
d Age 0–10 years (4 females and 6 males) (Struys et al. 1998).
e Age 20–55 years (12 females and 13 males).
Figure 1 Identification of SLC6A8 nonsense mutations in a white family with creatine-transporter deficiency. a, Pedigree. Affected in-
dividuals are indicated by completely blackened symbols, symptomatic carriers by half-blackened symbols, and the asymptomatic carrier by
the dot within a circle. b, Sequence analysis of DNA of the normal control, the mother of the index patient (individual “2-1” in panel a), and
the index patient (individual “3-1” in panel a). DNA was isolated from fibroblasts by DNAzol (GibcoBRL). PCR reactions were performed
with HotstarTaq (Qiagen), in a PE Applied Biosystems model 9700. PCR products were purified with PCR cleanup columns (Millipore).
Subsequently, these purified PCR products were sequenced by capillary electrophoresis, on an ABI PRISM 310 with the Big Dye terminator-
cycle sequencing kit (Perkin Elmer). Sequence analysis of part of exon 11—codons 512–516 (GenBank accession number NM_005629)—shows
that the CrT transition, 15239CrT, results in a 514RrX replacement. The index patient (individual “3-1” in panel a) is hemizygous for this
nonsense mutation, and the three females (individuals “1-1,” “2-1,” and “2-3” in panel a) are heterozygous for this nonsense mutation.
mother and increased for both the aunt and the mother.
In urine, creatine levels were increased in all three female
relatives. Urine and plasma of the mother were collected
during creatine treatment. Compared with those of age-
matched controls, MRS of the brains of both the mother
and the maternal aunt demonstrated a reduced, but de-
tectable, creatine signal.
The clinical presentation of the pedigree suggested an
X-linked disorder (fig. 1a). Our hypothesis therefore is
that this family suffers from a defect in the creatine-
transporter gene SLC6A8, located at Xq28. The gene
consists of 13 exons and spans ∼8.4 kb (GenBank ac-
cession number Z66539) (Sandoval et al. 1996). The
SLC6A8mRNA is ∼3.9 kb, and its predicted open-read-
ing frame encodes a protein of 635 amino acids, with a
molecular mass of ∼70 kD. Sequence analysis of am-
plified cDNA of SLC6A8 from fibroblasts of the index
patient revealed a hemizygous nonsense mutation. (For-
ward primer 5′-TTATTCCCTACGTCCTGATC and re-
verse primer 5′-GCTGGTGATGTGAGCTGAGT were
used to amplify the translated region of the mRNA,
which lacked the CG-rich exon 1, and separate primers
were designed to amplify exon 1.) A 1539CrT transition
in SLC6A8 (GenBank accession number NM_005629)
resulted in the substitution of an arginine codon by a
termination codon (R514rX). Amplification and direct
sequence analysis of exon 11 (by primers 5′-GTGGCCT-
GGGTGTACGGTAG and 5′-ATGAAGATGCCCTAC-
GGACC) from genomic DNA from fibroblasts of the
index patient confirmed this nonsense mutation (fig. 1b).
All three female relatives of the index patient were het-
erozygous for this mutation, as determined in genomic
DNA. Sequence analysis of cDNA from lymphoblasts of
the mother showed, almost equally, expression of both
the wild-type and the mutant allele, indicating stability
of the nonsense allele; no expression of themutant alleles
was detected in fibroblasts of the three female carriers,
which suggests X inactivation resulting in a mosaic ex-
pression of the mutant and wild-type alleles. In contrast
to the grandmother and the mother of the index patient,
the aunt of the index patient is asymptomatic. Skewed
X inactivation may explain this phenotypic difference
from the other two female carriers.
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Figure 2 Creatine uptake in fibroblasts of the index patient, in fibroblasts of two carriers (expressing only the wild-type SLC6A8) and
in cells of controls. a, Fibroblasts from the index patient (black), two carriers (gray), and two controls (white), cultured for 24 h in medium
(HAM/F10 supplemented with 10% fetal bovine serum, penicillin, and streptavidin) that contains 25 mM creatine. Creatine was added to obtain
final concentrations of 25, 125, and 500 mM, as indicated. b, Cells from the index patient, as well as cells from two carriers and from two
controls, were incubated with 500 mM creatine for 24 h, in either the absence (white) or the presence (gray) of 500 mM 3-guanidinopropionate,
an inhibitor of the creatine transporter. Prior to creatine measurement, the cells were washed twice with Hanks’ balanced salt solution. Cell
pellets were frozen until used. Protein concentrations were measured in 10% of the lysates, by the method used by Lowry. The lysates were
used to measure creatine concentrations after the addition of stable isotope–labeled creatine as the internal standard. Each value represents the
mean  SD of duplicate incubations from the index patient, from two carriers, or from two controls.
The nonsense mutation predicts a truncated protein
of 513 amino acids that lacks 122 amino acids of the
C-terminus, including the putative transmembrane-
spanning domains XI and XII of SLC6A8, which include
21 conserved amino acids (Nash et al. 1994). Domains
IX–XI are thought to be responsible for substrate-spec-
ificity differences among the neurotransmitter-trans-
porter subfamily, because these domains vary most
among this subfamily of proteins (Nash et al. 1994).
However, the nonsense mutation most likely results in
an unstable and/or inappropriately folded protein that
is completely inactive. To study creatine uptake in fi-
broblasts expressing the SLC6A8-null allele only, fibro-
blasts of the index patient were incubated for 24 h in
the presence of different concentrations of creatine. Fi-
broblasts from a group of controls—comprising the
mother and the grandmother of the index patient, who
both express only the wild-type SLC6A8 allele, and two
female patients with an unrelated disease—were ana-
lyzed. Creatine uptake was measured in total cell lysates,
by gas chromatography–mass spectrometry (GCMS)
with stable isotope–labeled creatine as the internal stan-
dard. When cells from the index patient were incubated
at a physiological-creatine concentration of 25 mM, cre-
atine uptake was negligible (fig. 2a) (Wyss and Kad-
durah-Daouk 2000). Even at 125 mM creatine, no up-
take could be measured, confirming the absence of a
functional creatine transporter in cells from the index
patient. At higher creatine concentrations (500 mM), cre-
atine uptake in the index patient’s cells was approxi-
mately one-third of that in the control cells. This most
likely represents either passive diffusion across the
plasma membrane or, alternatively, transport of creatine
via other neurotransmitter transporters; indeed, 24-h in-
cubations with 500 mM creatine in the presence of 500
mM guanidinopropionate, an inhibitor of the creatine
transporter, showed a twofold decrease in uptake in the
cells of both carriers and controls but not in the cells of
the index patient, supporting both assumptions (fig. 2b).
No significant creatine-uptake difference was observed
between cells of the carriers and those of the controls.
Recently, two sisters with reversible creatine deficiency
in the brain, a syndrome presumed to be the result of a
creatine-transporter defect in the brain, have been de-
scribed elsewhere (Bianchi et al. 2000). Mutation de-
tection in SLC6A8 was not reported. In contrast to our
index patient, the sisters clinically improved through cre-
atine supplementation. That the patients are females and
that they respond to creatine supplementation suggests
yet another creatine-deficiency syndrome. Alternatively,
the sisters, in comparison with their healthy mother, may
have a milder creatine-transporter defect that is the result
of a less-severe transporter mutation combined with un-
favorable X-linked mosaicism.
Thus far, five patients with GAMT deficiency have
been reported (Sto¨ckler et al. 1996a, 1996b; Schulze et
al. 1997; van der Knaap et al. 2000) who presented with
developmental delay (severe speech and language delay),
extrapyramidal movement abnormalities, hypotonia,
and the absence of creatine and phosphocreatine inMRS
of the brain. Furthermore, all patients showed increased
concentrations of GUAC in their bodily fluids. The clin-
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ical features, as well as the striking absence of creatine
in MRS of the brain, are also encountered in our index
patient, who suffered from a creatine-transporter defect.
In contrast to what has been reported in patients with
GAMT deficiency, GUAC levels in bodily fluids were not
increased in our index patient. The similarity of clinical
symptoms observed in both creatine-deficiency syn-
dromes suggests that the disturbed creatine pool, rather
than the increased GUAC levels, is important in the path-
ogenesis of GAMT deficiency.
In summary, we have described a new X-linked cre-
atine-deficiency syndrome, which is confirmed by a
hemizygous nonsense mutation in SLC6A8 of a male
index patient. Moreover, three female relatives of the
index patient are heterozygous for this mutation. The
laboratory hallmarks of this disease are the absence of
creatine in the MRS of the brain, an increase of creatine
in urine, and the presence of a severe mutation in the
X-mapped SLC6A8. Clinically, the severe language de-
lay, mild retardation, and X-linked inheritance in the
family are the most prominent characteristics of this dis-
ease. As yet, no clinical improvement has been observed
during creatine supplementation. Patients with less-se-
vere mutations (i.e., missense mutations) may have
milder clinical signs. It may prove worthwhile to screen
patients with behavioral and/or cognitive syndromes, for
decreased creatine signals in MRS, increased levels of
creatine in bodily fluids, and/or mutational analysis of
the creatine-transporter gene.
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